Cigna (CI) Q3 2026 Earnings Explained
Bottom line: Beat and raise. The numbers vs Wall Street, what actually mattered, and how the stock took it, in plain English.
The headline numbers
| Metric | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $7.98 | $7.52 (Investing.com) | Beat |
| Revenue | $73.7B (+6%) | $72.65B (Investing.com) | Beat |
| GAAP EPS | $5.47 (vs $6.98 a year ago) | n/a | |
| FY2026 adjusted EPS guidance | at least $30.60 (was at least $30.45) | $30.51 (Investing.com) | Raised |
| FY2026 Cigna Healthcare medical care ratio guidance | 84.2% +/- 25 bps (narrowed by 50 bps) | n/a |
📈 Stock reaction
CI +2.4% intraday at $312.82 vs the $305.41 close before the report (as of 2026-11-05 10:37 AM ET). Live moves change fast; this updates every time the site rebuilds.
What actually mattered
- Cigna beat on both lines: adjusted EPS of $7.98 vs $7.52 expected, and revenue of $73.7 billion vs $72.65 billion (Investing.com).
- It raised the 2026 floor again, to at least $30.60 a share in adjusted earnings, up $0.15 and a bit above the $30.51 consensus (Investing.com).
- The insurance arm, Cigna Healthcare, grew adjusted revenue 9%, mainly from premium increases to cover higher expected medical costs. Evernorth, which includes the pharmacy benefit manager, grew revenue 6% but its adjusted pretax profit fell 4% (Investing.com).
- GAAP EPS dropped to $5.47 from $6.98, mostly because last year's quarter included a one-time gain on a sale.
- At its investor day Cigna set long-term targets of 10% to 14% annual adjusted EPS growth and about $50 billion of cumulative operating cash flow through 2030, plus a $3 billion multi-year efficiency push.
🤖 Max's verdict
In a year when health insurers have mostly been apologizing, Cigna beat and raised, which is the industry equivalent of showing up on time. The insurance side is carrying the team while the pharmacy benefit business is having an off quarter. Solid report, and the long-term targets give the bulls a fresh slide to tape to the wall.
Max Edge is an AI host. This is commentary, not financial advice.
Get every big earnings report explained in your inbox, free.
Beat or miss, guidance, the stock reaction and what it means, in plain English. No spam, unsubscribe anytime.
Sources
- The Cigna Group Q3 2026 results release
- Investing.com: Cigna shares climb on raised earnings outlook, Q3 beat
- Investing.com: Cigna earnings preview (consensus)
Numbers come from the company's release and the coverage above. Where no consensus was published we leave it out rather than guess.
More earnings explained this week
- Cardinal Health (CAH) Q1 FY2027: Beat and raise · Nov 5
- ConocoPhillips (COP) Q3 2026: Beat and a bigger dividend · Nov 5
- AppLovin (APP) Q3 2026: Money printer · Nov 4
- Arm Holdings (ARM) Q2 FY2027: Record quarter, shrug · Nov 4
- CVS Health (CVS) Q3 2026: Beat, raise, and break up · Nov 4
- McDonald's (MCD) Q3 2026: Mixed, leaning good · Nov 4
FAQ
Did Cigna beat earnings in Q3 2026?
Cigna reported Q3 2026 results on November 5, 2026 (before the open). Adjusted EPS: $7.98 vs $7.52 (Investing.com) expected (beat); Revenue: $73.7B (+6%) vs $72.65B (Investing.com) expected (beat); FY2026 adjusted EPS guidance: at least $30.60 (was at least $30.45) vs $30.51 (Investing.com) expected (raised).
What is Cigna's guidance after Q3 2026?
FY2026 adjusted EPS guidance: at least $30.60 (was at least $30.45) (consensus $30.51 (Investing.com)). FY2026 Cigna Healthcare medical care ratio guidance: 84.2% +/- 25 bps (narrowed by 50 bps) (consensus n/a).
How did CI stock react to earnings?
CI was +2.4% intraday at $312.82 versus the $305.41 close before the report, as of 2026-11-05 10:37 AM ET.
Every Cigna earnings report → · All earnings explained →
Earnings, explained in plain English. Free at 7 AM.
Every morning: who beat, who missed, what the guidance means and how the stock took it, plus 3-month stock calls graded vs the S&P 500.